Gilead chairman & CEO O’Day sells $2.2m in stock

Daniel Patrick O’Day, Chairman and CEO of Gilead Sciences, sold 15,000 shares of the company’s stock on October 1, 2026, generating $2.2 million. Transactions occurred within a price range of $147.21 to $149.13, as per a pre-approved trading plan adopted on February 25, 2026. After the sale, O’Day still owned 566,683 shares of Gilead Sciences.

This move comes as Gilead’s stock approaches its 52-week high, currently priced at $160.51, delivering a 29.5% return year-to-date. However, the stock seems overvalued according to InvestingPro analysis. Gilead Sciences reported better-than-expected earnings for Q2 2026, with adjusted earnings per share losing $6.75 and revenue reaching $7.8 billion.

Key products like HIV, PrEP, oncology, and liver disease contributed significantly to the results. Despite $11.2 billion in IPR&D charges from recent acquisitions, the company remains focused on strategic partnerships and collaborations, such as a $10 million option with MacroGenics and a cost-sharing agreement with Assembly Biosciences for their herpes simplex virus program.